Endoscopic versus Shunt Treatment of Hydrocephalus in Infants
Endoscopic versus Shunt Treatment of Hydrocephalus in Infants
批准号:
10706453
负责人:
Richard Holubkov
金额:
$154.44万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-09-15 至 2027-08-31
关键词:
1 year oldAbdomenAccountingAffectAgeAge YearsAmericanAnisotropyBrainCauterizeCerebrospinal FluidCerebrospinal fluid shunts procedureCerebrumChildChildhoodClinical ResearchCognitiveCorpus CallosumCorticospinal TractsDataDevelopmentDiffusionDiffusion Magnetic Resonance ImagingFamilyHospital ChargesHydrocephalusImageInfantLanguageLength of StayLifeMeasuresMethodsMotorNCAM1 geneNeurologicNorth AmericaOperative Surgical ProceduresOutcomePediatric HospitalsPerformancePostoperative PeriodProceduresQuality of lifeRepeat SurgeryRiskShunt DeviceStructure of choroid plexusSurveysToddlerTreatment FailureVentricularVentriculostomycohortinsightneurosurgeryoptimal treatmentsprimary outcomerandomized trialtertiary caretreatment armwhite matter
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Hydrocephalus primarily affects infants under one year of age. The traditional treatment for hydrocephalus is
cerebrospinal fluid (CSF) shunt. Life-time complications of CSF shunts are high and expensive, with annual
hospital charges of nearly $2.0 billion, accounting for 3.1% of all pediatric hospital charges. As shunt
complications also adversely impact quality of life, it is not surprising that surveys of families affected by
hydrocephalus show that they desperately desire shunt-free treatment options. The most promising shunt-free
treatment for infant hydrocephalus is endoscopic third ventriculostomy with choroid plexus cauterization
(ETV+CPC), which our Hydrocephalus Clinical Research Network (HCRN) and others have shown to be safe
and viable. However, the cognitive outcome of ETV+CPC compared to shunt is not known. Our data suggest
that most families would accept the risks of ETV+CPC for the chance to be free of shunt, but only if initial
treatment with ETV+CPC will not lead to noticeable sacrifice in cognitive outcome compared to shunting. With
this U01 proposal, we aim: 1. To determine, in infants ≤12 months corrected age, with hydrocephalus requiring
treatment at tertiary care pediatric neurosurgery centers in North America, does ETV+CPC compared to shunt
result in non-inferior cognitive outcome at 12 months from surgery, as measured by Bayley Scales of Infant and
Toddler Development (Bayley-III) Cognitive Scale with a non-inferiority margin of 1.5. 2a. To determine, in
the same cohort, if ETV+CPC compared to shunt results in non-inferior Bayley-III Motor/Language Scales or
Vineland-3 Scales. 2b. To compare other measures of treatment performance (brain/ventricle volume,
treatment failure, hospital days, repeat surgery, use of imaging) and complications between treatment arms.
3a. To determine the effect of ETV+CPC and shunt on cerebral structural connectivity, with diffusion MR
fractional anisotropy (FA) in the corpus callosum 12 months after surgery. 3b. To define the relationships
between pre-operative brain/ventricular volume and cerebrospinal fluid (CSF) NCAM-1 level to post-operative
corpus callosum FA and Bayley-III Cognitive Scale 12 months after surgery. 3c. To define the relationships
between change in brain/ventricular volume (pre-operatively to 12 months post-operatively) to FA in the
corpus callosum and corticospinal tract and Bayley-III Cognitive and Motor Scales 12 months post-operatively.
To do this, we plan an RCT comparing ETV+CPC and shunt in infants with hydrocephalus, within the HCRN, a
committed group of 14 leading North American pediatric neurosurgical centers with a long track-record of
successful collaborative clinical research and RCTs in hydrocephalus. Optimal cognitive outcome, the primary
concern of families, will therefore, be our primary outcome. Assessment of dMRI, a validated, non-invasive
method of measuring white matter microstructural integrity and structural connectivity in the developing
brain, will provide further insight into the developmental consequences of these 2 treatments. This RCT will
help families determine the optimal treatment of hydrocephalus for their child.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Endoscopic third ventriculostomy in previously shunt-treated patients.
对既往接受过分流治疗的患者进行内镜下第三脑室造口术。
DOI:
10.3171/2022.6.peds22177
发表时间:
2022
期刊:
Journal of neurosurgery. Pediatrics
影响因子:
--
作者:
[Rocque,BrandonG, Jensen,Hailey, Reeder,RonW, Kulkarni,AbhayaV, Pollack,IanF, Wellons,JohnC, Naftel,RobertP, Jackson,EricM, Whitehead,WilliamE, Pindrik,JonathanA, Limbrick,DavidD, McDonald,PatrickJ, Tamber,MandeepS, Hankinson,Todd]
通讯作者:
Hankinson,Todd
A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial
-
批准号:10279146
-
项目类别:
-
资助金额:$305.54万
-
财政年份:2021
-
负责人:Richard Holubkov
-
依托单位:
A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial
-
批准号:10494229
-
项目类别:
-
资助金额:$337.83万
-
财政年份:2021
-
负责人:Richard Holubkov
-
依托单位:
Endoscopic versus Shunt Treatment of Hydrocephalus in Infants
-
批准号:10242095
-
项目类别:
-
资助金额:$149.22万
-
财政年份:2019
-
负责人:Richard Holubkov
-
依托单位:
Endoscopic versus Shunt Treatment of Hydrocephalus in Infants
-
批准号:10016833
-
项目类别:
-
资助金额:$149.77万
-
财政年份:2019
-
负责人:Richard Holubkov
-
依托单位:
海外基金